专利号:US-9315483-B2 优先权日:2007-09-13 标题 :Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof 发明人:JONES ANDREW D; ZELLE ROBERT E; SILVERMAN I ROBERT 权利人:CONCERT PHARMACEUTICALS INC 摘要:The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.
专利号:US-2024082118-A1 优先权日:2021-05-19 标 题:Topical compositions and methods of preparing the same 发明人:ABRAMOVICH SAGI; AVIDOR GAL; LANDA BENZION 权利人:LANDA LABS 2012 LTD 摘要:There is disclosed a composition comprising a water-insoluble thermoplastic compound capable of stimulating collagen synthesis (CSSC), the CSSC having a molecular weight of more than 0.6 kDa and being dispersed in a polar carrier as nano-elements having an average diameter of 200 nm or less and a viscosity of 107 mPa·s or less. The nano-elements of CSSC can be capable of stimulating the synthesis of skin proteins and/or enabling the delivery of active agents upon their application to a surface to be treated therewith. Methods for preparing the compositions and uses thereof are also provided.
专利号:US-2006009435-A1 优先权日:2004-06-23 标 题:Synthesis and powder preparation of fluticasone propionate 发明人:KASPI JOSEPH; ARAD ODED; BRAND MICHAEL; SHOOKRUN MOTY; MALKA SIMONA; ALNABARI MOHAMMED; HAZAN SHALOM; MALESEVIC VLADO 权利人:KASPI JOSEPH; ARAD ODED; BRAND MICHAEL; SHOOKRUN MOTY; MALKA SIMONA; ALNABARI MOHAMMED; HAZAN SHALOM; MALESEVIC VLADO 摘要:An improved process for preparing fluticasone propionate, performed in the presence of water, is disclosed. Further disclosed is a process for preparing a fluticasone propionate that is highly suitable for administration by inhalation. Further disclosed are fluticasone propionate and a powdered fluticasone propionate prepared by these processes and pharmaceutical compositions for administration by inhalation containing same. A process of purifying a key intermediate in the synthesis of fluticasone propionate is also disclosed.
专利号:US-7208613-B2 优先权日:2002-06-20 标 题:Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate 发明人:JADAV KANAKSINH JESINGBHAI; KAMBHAMPATI SUDHAKAR; CHITTURI TRINADHA RAO; THENNATI RAJAMANNAR 权利人:SUN PHARMACEUTICAL IND LTD 摘要:The present invention provides a convenient process for the preparation of S-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate, a compound of formula 1, comprisingn (a) treating 17β-[(N,N-dimethylcarbamoyl)thio]carbonyl-6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene, a compound of formula 3 with alkali metal carbonate-alcohol system to obtain 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioic acid, a compound of formula 4; (b) reacting the compound of formula 4 with bromofluoromethane to yield the compound of formula 1.
专利号:US-9051302-B2 优先权日:2008-01-15 标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents 发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN 权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG 摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.
专利号:US-8802660-B2 优先权日:2007-03-12 标 题:De novo synthesis of glucocorticoids in the epidermis and its uses and applications 发明人:TOMIC-CANIC MARJANA; BREM HAROLD; SAMUELS HERBERT H 权利人:TOMIC-CANIC MARJANA; BREM HAROLD; SAMUELS HERBERT H; UNIV NEW YORK 摘要:The present invention relates to methods and compositions that control, i.e., antagonize/inhibit or agonize/stimulate, de novo glucocorticoid production in the skin. Such methods and compositions can be used for the prevention and/or treatment of a variety of skin conditions, including inflammation, acute wounds, chronic non-healing wounds, keloid, fibrotic or hypertrophic scars, and epithelial-derived cancer.
1. Zhang M, Si SJ, Dai WJ, Yang J, Wang Y, Wei XR, Liu S, Xu CY, Zhang C, Jin F, Jiang LQ. A large particle size is required by a nano/micron sized-fluticasone propionate inhalable suspension for asthma treatment. Colloids Surf B Biointerfaces. 2023 May 24;228:113364. doi: 10.1016/j.colsurfb.2023.113364. Epub ahead of print. 14:1184552. doi: 10.3389/fphar.2023.1184552. 3. Passali D, Passali GC, Damiani V, Ciprandi G. Azelastine/fluticasone and allergic rhinitis in clinical practice. Eur Arch Otorhinolaryngol. 2023 Jun 5. doi: 10.1007/s00405-023-08006-9. Epub ahead of print. 15(4):e38334. doi: 10.7759/cureus.38334. 6. Oosterholt S, Pavord ID, Brusselle G, Yorgancıoğlu A, Pitrez PM, Abhijith PG, Teli C, Pasqua OD. Modelling Asthma TrEatment Responses (MASTER): Effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: a time-to-event analysis of randomised clinical trials. Br J Clin Pharmacol. 2023 May 23. doi: 10.1111/bcp.15801. Epub ahead of print. 8. Lee EG, Kim Y, Hwang YI, Yoo KH, Lee SE, Jung KY, Lee D, Park YB, Rhee CK. Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD. Sci Rep. 2023 May 20;13(1):8183. doi: 10.1038/s41598-023-35223-3. 9. Syverson EP, Tobin M, Patton T, Franciosi JP, Gupta SK, Venkatesh RD. Variability in Swallowed Topical Corticosteroid Practice Patterns for Treatment of Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023 May 18. doi: 10.1097/MPG.0000000000003834. Epub ahead of print. TRACK (Triple therapy for Japanese with mild to moderate COPD in Kyushu) study investigator group. Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study. BMJ Open Respir Res. 2023 May;10(1):e001607. doi: 10.1136/bmjresp-2022-001607. 314:104072. doi: 10.1016/j.resp.2023.104072. Epub ahead of print. 14:1131949. doi: 10.3389/fphys.2023.1131949. 13. Castro K, Arostegui D, Schwarz S, Gandhi S, Peshimam J, Rabinowitz S, Pittman M, Wallach T. Histologically Remarkable Eosinophilic Esophagitis Responsive to Dupilumab in a Gastrostomy Tube-Dependent Pediatric Patient on Amino Acid Formula. JPGN Rep. 2022 Sep 1;3(4):e250. doi: 10.1097/PG9.0000000000000250. 14. Sethi S, Clark B, Bengtson LGS, Buysman EK, Palli S, Sargent A, Shaikh A, Ferguson GT. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History. Int J Chron Obstruct Pulmon Dis. 2023 Apr 19;18:625-641. doi: 10.2147/COPD.S386962. 15. Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol. J Manag Care Spec Pharm. 2023 May
合成参考文献
参考文献:10.1272/jnms.77.21 摘要:Nonaka M, Sakanushi A, Kusama K, Ogihara N, Yagi T. One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma. J Nippon Med Sch. 2010 Feb;77(1):21–8. doi: 10.1272/jnms.77.21. 摘要:Patel M, Perrin K, Beasley R. Beta agonist use during asthma exacerbations: how much is too much N Z Med J. 2011 Apr 15;124(1332):77–80. 参考文献:10.2147/opth.s6541 摘要:Donnenfeld ED. Difluprednate for the prevention of ocular inflammation postsurgery: an update. Clin Ophthalmol. 2011;5():811–6. 参考文献:10.1007/s00535-011-0435-5 摘要:Fujishiro H, Amano Y, Kushiyama Y, Ishihara S, Kinoshita Y. Eosinophilic esophagitis investigated by upper gastrointestinal endoscopy in Japanese patients. J Gastroenterol. 2011 Sep;46(9):1142–4. doi: 10.1007/s00535-011-0435-5. 参考文献:10.1002/ppul.21499 摘要:Pedersen S, Maspero J, Gul N, Sharma R. Components of asthma control and treatment response of individual control criteria in children: analysis of the PEACE study. Pediatr Pulmonol. 2011 Dec;46(12):1182–8. doi: 10.1002/ppul.21499.